Suzhou Weichao Biotechnology

Suzhou Weichao Biotechnology is a Chinese biopharmaceutical company focused on the discovery and development of innovative antibody-based therapeutics for oncology and autoimmune diseases. The company leverages its proprietary antibody discovery platform to generate high-affinity monoclonal and multi-specific antibodies, as well as next-generation antibody-drug conjugates (ADCs). Weichao Biotech aims to address unmet medical needs by targeting validated and novel pathways such as Claudin 18.2 and immune checkpoints. Headquartered in the Suzhou Industrial Park (BioBAY), the company is positioned within one of China's premier biotechnology hubs to facilitate rapid R&D and clinical translation.